Randomisation Sample Clauses

Randomisation. The randomisation will be done in a 2:2:1:1 ratio to one of four treatment sequences: During analysis of study Treatment 1, the two placebo containing sequences will be pooled into a single arm. Randomisation will be stratified by: 1) Aetiology of NDO (SCI or MS) 2) Previous intradetrusor BTX-A usage for UI (BTX-A naive vs. BTX-A non-naive in the bladder). The spousor's raudomisatiou mauager who is a statisticiau iudepeudent from the study, will prepare three lists which will be performed in blocks and will be based on computer-generated randomisation lists: • List A: a list of randomisation numbers, which will be produced in an unbalanced ratio 2:2:1:1 for the four treatment sequences and which will be stratified by aetiology and prior intradetrusor BTX-A usage for UI • List B: a list of double blind treatment numbers, which will be specified on the treatment packs to be dispatched to the sites in order to dispense the drug in Treatment 1 and possibly for subsequent retreatments. It will be produced in a balanced ratio 1:1:1 for 600 U Dysport®, 800 U Dysport® and placebo • List C: a list of double blind treatment numbers, which will be specified on the treatment packs to be dispatched to the sites in order to dispense the drug for retreatments (but not in Treatment 1). It will be produced in a balanced ratio 1:1 for 600 U Dysport® and 800 U Dysport®. In order to maintain a balanced treatment sequence ratio of 2:2:1:1 in both the urodynamic and non-urodynamic subsets, the randomisation number(s) may be skipped in accordance with the procedure below. The purpose of skipping randomisation number(s) will be to ensure that the number of subjects in each treatment sequence will remain within five subjects of the required number to maintain a treatment sequence ratio of 2:2:1:1 within the subset. Any skipped randomisation number(s) will then be used in priority at subsequent randomisations. This process will be programmed into the interactive response technology (IRT) and will occur automatically (with no human intervention). Using the following values for the concerned subset: a = number of subjects in sequence 1 b = number of subjects in sequence 2 c = number of subjects in sequence 3 d = number of subjects in sequence 4 The IRT will skip randomisation number(s) to maintain the following conditions: • RANGE(a/2,b/2,c,d)<5 • RANGE(a,b)<5 • RANGE(c,d)<5 • RANGE(a,c+d)<5 • RANGE(b,c+d)<5 • RANGE(a+c,b+d)<5 The assignment of randomisation and treatment numbers at ...
Sample 1
AutoNDA by SimpleDocs
Randomisation. Randomisation was made using 40 closed envelopes each containing a piece of paper with either Mindfulness or Relaxation written on it. After participants completed the measures, the researcher picked one envelope and allocated the participant to the assigned intervention.
Sample 1
Randomisation. Eligible and consenting participants were randomised to the CTI or TAU by block randomisation, stratified by prison, after participants had been consented and baseline assessments were complete. Participants were fully informed about the randomisation procedure and knew that they may receive CTI or TAU. Randomisation was undertaken by the King's Clinical Trials Unit, utilising a process of concealment, using an online system and there was full allocation concealment. Data were entered onto the online InferMed MACRO data entry system that is managed by the King’s Clinical Trials Unit. The researcher was notified of the randomisation outcome immediately and communicated this information to the participant, the CTI manager and to the clinical team. Because of the nature of the intervention, it was not possible to blind participants, researchers, CTI managers or mental health inreach team staff to the treatment allocation. The researchers were required to review participants’ prison and community mental health records, where information on allocation was usually present, and the project’s funding did not allow arrangements to avoid this. In addition, the researchers were based in the mental health inreach team office along with the CTI manager and information regarding allocation was displayed in this office.
Sample 1

Related to Randomisation

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Random Testing Notwithstanding any provisions of the Collective Agreement or any special agreements appended thereto, section 4.6 of the Canadian Model will not be applied by agreement. If applied to a worker dispatched by the Union, it will be applied or deemed to be applied unilaterally by the Employer. The Union retains the right to grieve the legality of any imposition of random testing in accordance with the Grievance Procedure set out in this Collective Agreement.

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

  • Technical and Organisational Measures (1) Before the commencement of processing, the Supplier shall document the execution of the necessary Technical and Organisational Measures, set out in advance of the awarding of the Order or Contract, specifically with regard to the detailed execution of the contract, and shall present these documented measures to the Client for inspection. Upon acceptance by the Client, the documented measures become the foundation of the contract. Insofar as the inspection/audit by the Client shows the need for amendments, such amendments shall be implemented by mutual agreement. (2) The Supplier shall establish the security in accordance with Article 28 Paragraph 3 Point c, and Article 32 GDPR in particular in conjunction with Article 5 Paragraph 1, and Paragraph 2 GDPR. The measures to be taken are measures of data security and measures that guarantee a protection level appropriate to the risk concerning confidentiality, integrity, availability and resilience of the systems. The state of the art, implementation costs, the nature, scope and purposes of processing as well as the probability of occurrence and the severity of the risk to the rights and freedoms of natural persons within the meaning of Article 32 Paragraph 1 GDPR must be taken into account. [Details in Appendix 1] (3) The Technical and Organisational Measures are subject to technical progress and further development. In this respect, it is permissible for the Supplier to implement alternative adequate measures. In so doing, the security level of the defined measures must not be reduced. Substantial changes must be documented.

  • Third Party Verification 4.8.1 The SPD shall be further required to provide entry to the site of the Power Project free of all encumbrances at all times during the Term of the Agreement to SECI and a third Party nominated by any Indian Governmental Instrumentality for inspection and verification of the works being carried out by the SPD at the site of the Power Project. 4.8.2 The third party may verify the construction works/operation of the Power Project being carried out by the SPD and if it is found that the construction works/operation of the Power Project is not as per the Prudent Utility Practices, it may seek clarifications from SPD or require the works to be stopped or to comply with the instructions of such third party.

  • Clinical 1.1 Provides comprehensive evidence based nursing care and individual case management to a specific group of patients/clients including assessment, intervention and evaluation. 1.2 Undertakes clinical shifts at the direction of senior staff and the Nursing Director including participation on the on-call/after-hours/weekend roster if required. 1.3 Responsible and accountable for patient safety and quality of care through planning, coordinating, performing, facilitating, and evaluating the delivery of patient care relating to a particular group of patients, clients or staff in the practice setting. 1.4 Monitors, reviews and reports upon the standard of nursing practice to ensure that colleagues are working within the scope of nursing practice, following appropriate clinical pathways, policies, procedures and adopting a risk management approach in patient care delivery. 1.5 Participates in xxxx rounds/case conferences as appropriate. 1.6 Educates patients/carers in post discharge management and organises discharge summaries/referrals to other services, as appropriate. 1.7 Supports and liaises with patients, carers, colleagues, medical, nursing, allied health, support staff, external agencies and the private sector to provide coordinated multidisciplinary care. 1.8 Completes clinical documentation and undertakes other administrative/management tasks as required. 1.9 Participates in departmental and other meetings as required to meet organisational and service objectives. 1.10 Develops and seeks to implement change utilising expert clinical knowledge through research and evidence based best practice. 1.11 Monitors and maintains availability of consumable stock. 1.12 Complies with and demonstrates a positive commitment to Regulations, Acts and Policies relevant to nursing including the Code of Ethics for Nurses in Australia, the Code of Conduct for Nurses in Australia, the National Competency Standards for the Registered Nurse and the Poisons Act 2014 and Medicines and Poisons Regulations 2016. 1.13 Promotes and participates in team building and decision making. 1.14 Responsible for the clinical supervision of nurses at Level 1 and/or Enrolled Nurses/ Assistants in Nursing under their supervision.

  • Protocol The attached Protocol shall be an integral part of this Agreement.

  • Abuse and Neglect of Children and Vulnerable Adults: Abuse Registry Party agrees not to employ any individual, to use any volunteer or other service provider, or to otherwise provide reimbursement to any individual who in the performance of services connected with this agreement provides care, custody, treatment, transportation, or supervision to children or to vulnerable adults if there has been a substantiation of abuse or neglect or exploitation involving that individual. Party is responsible for confirming as to each individual having such contact with children or vulnerable adults the non-existence of a substantiated allegation of abuse, neglect or exploitation by verifying that fact though (a) as to vulnerable adults, the Adult Abuse Registry maintained by the Department of Disabilities, Aging and Independent Living and (b) as to children, the Central Child Protection Registry (unless the Party holds a valid child care license or registration from the Division of Child Development, Department for Children and Families). See 33 V.S.A. §4919(a)(3) and 33 V.S.A. §6911(c)(3).

  • Plagiarism The appropriation of another person's ideas, processes, results, or words without giving appropriate credit.

  • Medical Verification The Town may require medical verification of an employee’s absence if the Town perceives the employee is abusing sick leave or has used an excessive amount of sick leave. The Town may require medical verification of an employee’s absence to verify that the employee is able to return to work with or without restrictions.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!